Abstract
Chronic kidney disease (CKD), and particularly kidney failure, is associated with accelerated atherosclerosis and approximately a 20-fold increased risk of cardiovascular death. The majority of these patients die from complications directly attributed to atherosclerosis and their life expectancy is decreased. Established risk factors are involved in the pathogenesis of this phenomenon. Age, gender, smoking, hypertension, dyslipidaemia and diabetes mellitus are among the established risk factors. Inflammation, qualitative lipid disorders (e.g. small dense low density lipoprotein), vascular calcification and oxidative stress represent emerging risk factors. The precise mechanism of atherosclerosis in patients with kidney failure is not yet known. CKD might represent a clinical model of atherogenesis. Thus, the evidence obtained from investigating “renal” atherogenesis could be of interest in improving our understanding of this disease process in the non-renal population. We review the relationship between “renal” and non-renal atherosclerosis focusing on pathogenesis, risk factors and clinical events and how they interact with treatment options. Overall, the “later” stages of CKD may eventually be considered as a coronary heart disease equivalent condition.
Keywords: Atherosclerosis, calcification, oxidative stress, inflammation, hypertension, glomerulosclerosis, chronic kidney disease, vascular disease
Current Vascular Pharmacology
Title: Atherogenesis in Renal Patients: A Model of Vascular Disease?
Volume: 6 Issue: 2
Author(s): Georgios Efstratiadis, Konstantinos Tziomalos, Dimitri P. Mikhailidis, Vasilios G. Athyros and Apostolos Hatzitolios
Affiliation:
Keywords: Atherosclerosis, calcification, oxidative stress, inflammation, hypertension, glomerulosclerosis, chronic kidney disease, vascular disease
Abstract: Chronic kidney disease (CKD), and particularly kidney failure, is associated with accelerated atherosclerosis and approximately a 20-fold increased risk of cardiovascular death. The majority of these patients die from complications directly attributed to atherosclerosis and their life expectancy is decreased. Established risk factors are involved in the pathogenesis of this phenomenon. Age, gender, smoking, hypertension, dyslipidaemia and diabetes mellitus are among the established risk factors. Inflammation, qualitative lipid disorders (e.g. small dense low density lipoprotein), vascular calcification and oxidative stress represent emerging risk factors. The precise mechanism of atherosclerosis in patients with kidney failure is not yet known. CKD might represent a clinical model of atherogenesis. Thus, the evidence obtained from investigating “renal” atherogenesis could be of interest in improving our understanding of this disease process in the non-renal population. We review the relationship between “renal” and non-renal atherosclerosis focusing on pathogenesis, risk factors and clinical events and how they interact with treatment options. Overall, the “later” stages of CKD may eventually be considered as a coronary heart disease equivalent condition.
Export Options
About this article
Cite this article as:
Efstratiadis Georgios, Tziomalos Konstantinos, Mikhailidis P. Dimitri, Athyros G. Vasilios and Hatzitolios Apostolos, Atherogenesis in Renal Patients: A Model of Vascular Disease?, Current Vascular Pharmacology 2008; 6 (2) . https://dx.doi.org/10.2174/157016108783955374
DOI https://dx.doi.org/10.2174/157016108783955374 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses)
Current Pharmaceutical Design From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Current Vascular Pharmacology Potential Role of TRP Channels in Cough Hypersensitivity?
Current Respiratory Medicine Reviews Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Recent Patents in Olive Oil Industry: New Technologies for the Recovery of Phenols Compounds from Olive Oil, Olive Oil Industrial by-Products and Waste Waters
Recent Patents on Food, Nutrition & Agriculture Subject Index to Volume 2
Current Vascular Pharmacology A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Magnetomotive Molecular Nanoprobes
Current Medicinal Chemistry Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology How to Investigate the Vascular Changes in Resistant Hypertension
Current Hypertension Reviews Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Review: Evidence-based Clinical Research of Anti-obesity Supplements in Japan
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Selenium Containing Compounds from Poison to Drug Candidates: A Review on the GPx-like Activity
Current Chemical Biology